# Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

> **NCT04391959** · PHASE2 · COMPLETED · sponsor: **Azura Ophthalmics** · enrollment: 31 (actual)

## Conditions studied

- Meibomian Gland Dysfunction

## Interventions

- **DRUG:** AZR-MD-001 Active
- **DRUG:** AZR-MD-001 Vehicle

## Key facts

- **NCT ID:** NCT04391959
- **Lead sponsor:** Azura Ophthalmics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-17
- **Primary completion:** 2021-01-06
- **Final completion:** 2021-01-06
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04391959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04391959, "Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04391959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*